These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 16631461)

  • 21. Is there a role for chemotherapy in prostate cancer?
    Canil CM; Tannock IF
    Br J Cancer; 2004 Sep; 91(6):1005-11. PubMed ID: 15150548
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Chemotherapy for prostate cancer].
    Medioni J; Dionysopoulos D; Banu E; Scotté F; Beuzeboc P; Oudard S
    Presse Med; 2008 May; 37(5 Pt 2):814-20. PubMed ID: 18160251
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.
    Oudard S; Banu E; Beuzeboc P; Voog E; Dourthe LM; Hardy-Bessard AC; Linassier C; Scotté F; Banu A; Coscas Y; Guinet F; Poupon MF; Andrieu JM
    J Clin Oncol; 2005 May; 23(15):3343-51. PubMed ID: 15738542
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systemic therapy after first-line docetaxel in metastatic castration-resistant prostate cancer.
    Beardsley EK; Chi KN
    Curr Opin Support Palliat Care; 2008 Sep; 2(3):161-6. PubMed ID: 18685415
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment options for androgen-independent prostate cancer.
    Gulley J; Figg WD; Dahut WL
    Clin Adv Hematol Oncol; 2003 Jan; 1(1):49-57. PubMed ID: 16227960
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The evolving role of docetaxel in the management of androgen independent prostate cancer.
    Khan MA; Carducci M; Partin AW
    J Urol; 2003 Nov; 170(5):1709-16. PubMed ID: 14532760
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Weekly docetaxel as second line treatment after mitozantrone for androgen-independent prostate cancer.
    Joshua AM; Nordman I; Venkataswaran R; Clarke S; Stockler MR; Boyer MJ
    Intern Med J; 2005 Aug; 35(8):468-72. PubMed ID: 16176469
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of docetaxel-based chemotherapy on quality of life of patients with castration-resistant prostate cancer: results from a prospective phase II randomized trial.
    Caffo O; Sava T; Comploj E; Fariello A; Zustovich F; Segati R; Sacco C; Veccia A; Galligioni E
    BJU Int; 2011 Dec; 108(11):1825-32. PubMed ID: 21615854
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Docetaxel in prostate cancer.
    Small EJ
    Anticancer Drugs; 2001 Feb; 12 Suppl 1():S17-20. PubMed ID: 11340899
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Prostate cancer and chemotherapy].
    Gravis G; Salem N; Bladou F; Viens P
    Bull Cancer; 2007 Jul; 94(7 Suppl):F21-8. PubMed ID: 17845990
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The use of estramustine phosphate in the modern management of advanced prostate cancer.
    Ravery V; Fizazi K; Oudard S; Drouet L; Eymard JC; Culine S; Gravis G; Hennequin C; Zerbib M
    BJU Int; 2011 Dec; 108(11):1782-6. PubMed ID: 21756277
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug insight: Use of docetaxel in prostate and urothelial cancers.
    Mackler NJ; Pienta KJ
    Nat Clin Pract Urol; 2005 Feb; 2(2):92-100; quiz 1 p following 112. PubMed ID: 16474654
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improving outcomes with recent advances in chemotherapy for castrate-resistant prostate cancer.
    Sartor O; Halstead M; Katz L
    Clin Genitourin Cancer; 2010 Dec; 8(1):23-8. PubMed ID: 21208852
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study.
    Berthold DR; Pond GR; Roessner M; de Wit R; Eisenberger M; Tannock AI;
    Clin Cancer Res; 2008 May; 14(9):2763-7. PubMed ID: 18451243
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chemotherapy for androgen-independent prostate cancer.
    Petrylak DP
    World J Urol; 2005 Feb; 23(1):10-3. PubMed ID: 15685445
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Shifting paradigms in prostate cancer; docetaxel plus low-dose prednisone - finally an effective chemotherapy.
    de Wit R
    Eur J Cancer; 2005 Mar; 41(4):502-7. PubMed ID: 15737553
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemotherapy-based treatment for castration-resistant prostate cancer.
    Seruga B; Tannock IF
    J Clin Oncol; 2011 Sep; 29(27):3686-94. PubMed ID: 21844499
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic options for hormone-refractory prostate cancer in 2007.
    Hadaschik BA; Gleave ME
    Urol Oncol; 2007; 25(5):413-9. PubMed ID: 17826663
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Response to vinorelbine with or without estramustine as second-line chemotherapy in patients with hormone-refractory prostate cancer.
    Nakabayashi M; Ling J; Xie W; Regan MM; Oh WK
    Cancer J; 2007; 13(2):125-9. PubMed ID: 17476141
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The case for early chemotherapy for the treatment of metastatic disease.
    Lucas A; Petrylak DP
    J Urol; 2006 Dec; 176(6 Pt 2):S72-5. PubMed ID: 17084173
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.